
Marjo M P C Donners

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6472469/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Two-faced Janus: the dual role of macrophages in atherosclerotic calcification. Cardiovascular Research, 2022, 118, 2768-2777.	3.8	20
2	ADAM10-Mediated Cleavage of ICAM-1 Is Involved in Neutrophil Transendothelial Migration. Cells, 2021, 10, 232.	4.1	17
3	Letter by van der Vorst et al Regarding Article, "Anti-Inflammatory Effects of HDL (High-Density) Tj ETQq1 1 0. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e31-e32.	784314 rg 2.4	gBT /Overloc 1
4	Shedding of Klotho: Functional Implications in Chronic Kidney Disease and Associated Vascular Disease. Frontiers in Cardiovascular Medicine, 2020, 7, 617842.	2.4	22
5	SCRIBbling the role of endothelial polarity in atherosclerosis. Cardiovascular Research, 2019, 115, 1937-1939.	3.8	1
6	Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis. Journal of Experimental Medicine, 2019, 216, 807-830.	8.5	31
7	ADAM8 in the cardiovascular system: An innocent bystander with clinical use?. Atherosclerosis, 2019, 286, 147-149.	0.8	1
8	Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. Blood Advances, 2018, 2, 2320-2331.	5.2	45
9	Message in a Microbottle: Modulation of Vascular Inflammation and Atherosclerosis by Extracellular Vesicles. Frontiers in Cardiovascular Medicine, 2018, 5, 2.	2.4	23
10	A Disintegrin and Metalloproteases (ADAMs) in Cardiovascular, Metabolic and Inflammatory Diseases: Aspects for Theranostic Approaches. Thrombosis and Haemostasis, 2018, 118, 1167-1175.	3.4	26
11	Disease- or Storage-Associated Structural Modifications Are Unlikely to Explain HDL Pro-inflammatory Effects on Macrophages. Cell Metabolism, 2017, 26, 4-5.	16.2	11
12	HDL and macrophages: explaining the clinical failures and advancing HDL-based therapeutics in cardiovascular diseases?. Expert Review of Cardiovascular Therapy, 2017, 15, 343-344.	1.5	2
13	Heterogeneity of atherosclerotic plaque macrophage origin, phenotype and functions: Implications for treatment. European Journal of Pharmacology, 2017, 816, 14-24.	3.5	30
14	Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression. Scientific Reports, 2017, 7, 11670.	3.3	13
15	High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via Passive Cholesterol Depletion and PKC-NF-I®B/STAT1-IRF1 Signaling. Cell Metabolism, 2017, 25, 197-207.	16.2	80
16	Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases. Mediators of Inflammation, 2017, 2017, 1-22.	3.0	21
17	Cathepsin K Deficiency Prevents the Aggravated Vascular Remodeling Response to Flow Cessation in ApoE-/- Mice. PLoS ONE, 2016, 11, e0162595.	2.5	9
18	Prevention of oxLDL uptake leads to decreased atherosclerosis in hematopoietic NPC1-deficient Ldlrâ^'/â^' mice. Atherosclerosis, 2016, 255, 59-65.	0.8	25

#	Article	IF	CITATIONS
19	ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses. Journal of Leukocyte Biology, 2016, 99, 749-760.	3.3	49
20	Myeloid A Disintegrin and Metalloproteinase Domain 10 Deficiency Modulates Atherosclerotic Plaque Composition by Shifting the Balance from Inflammation toward Fibrosis. American Journal of Pathology, 2015, 185, 1145-1155.	3.8	46
21	Platelet CD40L Modulates Thrombus Growth Via Phosphatidylinositol 3-Kinase β, and Not Via CD40 and lκB Kinase α. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1374-1381.	2.4	31
22	Bone marrowâ€specific caspaseâ€1/11 deficiency inhibits atherosclerosis development in <i>Ldlr</i> ^{<i>â^'/â^'</i>} mice. FEBS Journal, 2015, 282, 2327-2338.	4.7	60
23	Reversal of Hypoxia in Murine Atherosclerosis Prevents Necrotic Core Expansion by Enhancing Efferocytosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2545-2553.	2.4	56
24	Reprogramming macrophages to an antiâ€inflammatory phenotype by helminth antigens reduces murine atherosclerosis. FASEB Journal, 2014, 28, 288-299.	0.5	69
25	Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis, 2014, 17, 109-118.	7.2	649
26	Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space. Blood, 2014, 123, 4077-4088.	1.4	54
27	Regulation of adult hematopoiesis by the a disintegrin and metalloproteinase 10 (ADAM10). Biochemical and Biophysical Research Communications, 2013, 442, 234-241.	2.1	13
28	Cell surface-expressed phosphatidylserine as therapeutic target to enhance phagocytosis of apoptotic cells. Cell Death and Differentiation, 2013, 20, 49-56.	11.2	30
29	Local Delivery of Polarized Macrophages Improves Reperfusion Recovery in a Mouse Hind Limb Ischemia Model. PLoS ONE, 2013, 8, e68811.	2.5	41
30	A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis, 2012, 224, 302-308.	0.8	47
31	Hematopoietic miR155 Deficiency Enhances Atherosclerosis and Decreases Plaque Stability in Hyperlipidemic Mice. PLoS ONE, 2012, 7, e35877.	2.5	129
32	Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thrombosis and Haemostasis, 2011, 106, 763-771.	3.4	159
33	Feed-forward Signaling by Membrane-bound Ligand Receptor Circuit. Journal of Biological Chemistry, 2010, 285, 40681-40689.	3.4	52
34	A Disintegrin and Metalloprotease 10 Is a Novel Mediator of Vascular Endothelial Growth Factor–Induced Endothelial Cell Function in Angiogenesis and Is Associated With Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2188-2195.	2.4	94
35	The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood, 2008, 111, 4596-4604.	1.4	80
36	Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?. Expert Review of Cardiovascular Therapy, 2007, 5, 345-364.	1.5	11

MARJO M P C DONNERS

#	Article	IF	CITATIONS
37	CD40 and Its Ligand in Atherosclerosis. Trends in Cardiovascular Medicine, 2007, 17, 118-123.	4.9	104
38	Low-Dose FK506 Blocks Collar-Induced Atherosclerotic Plaque Development and Stabilizes Plaques in ApoE-/- Mice. American Journal of Transplantation, 2005, 5, 1204-1215.	4.7	24
39	Proteomic analysis of differential protein expression in human atherosclerotic plaque progression. Journal of Pathology, 2005, 206, 39-45.	4.5	51
40	Models of atherosclerosis and transplant arteriosclerosis: the quest for the best. Drug Discovery Today: Disease Models, 2004, 1, 257-263.	1.2	4
41	Inflammation and restenosis: implications for therapy. Annals of Medicine, 2003, 35, 523-531.	3.8	41
42	Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoEâ~'/â~Mice. Circulation Research, 2003, 93, 464-471.	4.5	59
43	Increased arterial expression of a glycosylated haptoglobin isoform after balloon dilation. Cardiovascular Research, 2003, 58, 689-695.	3.8	18